Cardiovascular Business

RAVR is a new minimally invasive treatment option for symptomatic severe AS that uses advanced robotic surgical systems. To learn more, Cardiovascular Business spoke to Vinay Badhwar, MD, executive chair of the WVU Heart and Vascular Institute at WVU Medicine and one of the world’s leading voices in robotic heart surgery.

As more and more high-risk patients undergo PCI, what is the best treatment strategy following an initial event-free period of DAPT? Does it change when complex PCI is required? Researchers aimed to answer those questions, and many others, with new research published in JAMA Cardiology.

The WVU Heart and Vascular Institute at WVU Medicine, already known as a leader in robotic heart surgeries, has now performed the world's first combined aortic valve replacement and CABG—all done robotically, through one small incision. The patient in question, a 73-year-old woman who presented with a history of stroke, brain surgery and ongoing weight loss, is recovering well.

Targeting aortic regurgitation with #TAVR valves built to treat aortic stenosis may be the only option a cardiologist has—but valves designed by JenaValve Technology, Inc. and JC Medical, Inc. specifically to treat AR are linked to much better outcomes, according to a new meta-analysis. Edwards Lifesciences acquired both JenaValve and JC Medical in 2024, highlighting the company's increased focused on TAVR technology moving forward.

Cardiologist Guilherme Attizzani, MD, spoke to Cardiovascular Business about the importance of commissural alignment during TAVR and why he feels confident treating patients with supra-annular, self-expanding transcatheter heart valves like the ones built by Medtronic.

🚨 Webinar Alert! Understanding plaque burden in CAD patients is critical for better outcomes. But how can you do it more accurately? Join us for an insightful discussion featuring two cardiologists as they explore: ✅ The benefits of coronary CTA + AI-driven plaque analysis
 ✅ How to assess cardiovascular event risks effectively
 ✅ Key takeaways from the 7-year ADVANCE-DK study Don’t miss this opportunity. Register now! https://ow.ly/nQws50Ukiif

“The single most important thing to focus on when it comes to TAVR valves is performance and longevity," cardiologist Deepak R. Talreja, MD, explained. Talreja pointed to the SMART trial and Evolut Low Risk Trial as two important TAVR studies from recent memory. He also praised the Evolut platform from Medtronic for its consistent benefits in terms of long-term durability.

Self-expanding Evolut TAVR valves designed by Medtronic were at the center of multiple studies presented during PCR London Valves 2024. One study presented during the three-day conference focused on the potential benefits of an optimized TAVR pathway. Another study, meanwhile, tracked changes in paravalvular leak severity over time.

Cardiac imaging case of the day in poster sessions at the Radiological Society of North America (RSNA). #RSNA24 #RSNA2024 #RSNA

Example of Materialise 3D printing of a heart with an interchangeable left atrial appendage (LAA) created from various patient CT scans on display in the Materialise booth at the Radiological Society of North America (RSNA) 2024 meeting this week. Good examples of “Chicken wing” shaped LAAs. #RSNA24 #RSNA2024 #RSNA #LAA #LAAO